Evicenter
P&T meetings

Relutrigine

SCN2A- and SCN8A-related developmental and epileptic encephalopathies

Regulatory submission
NDA submitted in early 2026
Launch
Not announced
72 sources

Section 6 of 6

References

72 sources

  1. Abbott et al. (2024) (opens in a new tab)
  2. Andersen et al. (2025) (opens in a new tab)
  3. Andrews et al. (2023) (opens in a new tab)
  4. Berg et al. (2021) (opens in a new tab)
  5. Berg et al. (2024) (opens in a new tab)
  6. Berg et al. (2025a) (opens in a new tab)
  7. Berg et al. (2025b) (opens in a new tab)
  8. Berg et al. (2025c) (opens in a new tab)
  9. Bialer et al. (2026) (opens in a new tab)
  10. ClinicalTrials.gov NCT05818553 (opens in a new tab)
  11. Cohen et al. (2022) (opens in a new tab)
  12. Conecker et al. (2024a) (opens in a new tab)
  13. Conecker et al. (2024a) (opens in a new tab)
  14. Conecker et al. (2024b) (opens in a new tab)
  15. Conecker et al. (2024b) (opens in a new tab)
  16. Cutts et al. (2022) (opens in a new tab)
  17. Dalby et al. (2022) (opens in a new tab)
  18. Densmore et al. (2021) (opens in a new tab)
  19. Downs et al. (2024) (opens in a new tab)
  20. DRKS DRKS00032614 (opens in a new tab)
  21. FamilieSCN2A Foundation (opens in a new tab)
  22. FDA Orphan Drug Designations and Approvals (2021) (opens in a new tab)
  23. Frizzo et al. (2025) (opens in a new tab)
  24. Gallop et al. (2021) (opens in a new tab)
  25. GeneReviews (opens in a new tab)
  26. Gjerulfsen et al. (2025) (opens in a new tab)
  27. Gjerulfsen et al. (2025) (opens in a new tab)
  28. Goad et al. (2025) (opens in a new tab)
  29. Johannesen et al. (2018) (opens in a new tab)
  30. Johannesen et al. (2021) (opens in a new tab)
  31. Kaat et al. (2025) (opens in a new tab)
  32. Kahlig et al. (2022) (opens in a new tab)
  33. Kahlig et al. (2022) (opens in a new tab)
  34. Kamireddy et al. (2025a) (opens in a new tab)
  35. Kamireddy et al. (2025b) (opens in a new tab)
  36. Kamireddy et al. (2026a) (opens in a new tab)
  37. Kamireddy et al. (2026b) (opens in a new tab)
  38. Krey et al. (2022) (opens in a new tab)
  39. Ludwig et al. (2024) (opens in a new tab)
  40. Ludwig et al. (2026) (opens in a new tab)
  41. Magielski et al. (2025) (opens in a new tab)
  42. MedlinePlus (opens in a new tab)
  43. Mesraoua et al. (2026) (opens in a new tab)
  44. Neurology (2023) (opens in a new tab)
  45. Oates et al. (2018) (opens in a new tab)
  46. Pfister et al. (2022) (opens in a new tab)
  47. Pfister et al. (2023a) (opens in a new tab)
  48. Pfister et al. (2023b) (opens in a new tab)
  49. Pfister et al. (2023c) (opens in a new tab)
  50. Praxis Precision Medicines (opens in a new tab)
  51. Praxis Precision Medicines (2024) (opens in a new tab)
  52. Praxis Precision Medicines (2024) (opens in a new tab)
  53. Praxis Precision Medicines (2025) (opens in a new tab)
  54. Praxis Precision Medicines (2025) (opens in a new tab)
  55. Praxis Precision Medicines (2025) (opens in a new tab)
  56. Praxis Precision Medicines (2026) (opens in a new tab)
  57. Praxis Precision Medicines (2026) (opens in a new tab)
  58. Praxis Precision Medicines (2026) (opens in a new tab)
  59. Praxis Precision Medicines (2026) (opens in a new tab)
  60. Praxis Precision Medicines (2026) (opens in a new tab)
  61. Praxis Precision Medicines presentation (2025) (opens in a new tab)
  62. Praxis Precision Medicines presentation (2026) (opens in a new tab)
  63. Prime Therapeutics (2026) (opens in a new tab)
  64. SCN8A Research Consortium (2025) (opens in a new tab)
  65. Sevinc et al. (2025) (opens in a new tab)
  66. Tan et al. (2026) (opens in a new tab)
  67. The Cute Syndrome Foundation (opens in a new tab)
  68. Wagner et al. (2026) (opens in a new tab)
  69. Wolff et al. (2017) (opens in a new tab)
  70. Xie et al. (2025) (opens in a new tab)
  71. Xie et al. (2025) (opens in a new tab)
  72. Zeng et al. (2022) (opens in a new tab)